Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIS Trial
DRKS00011857Phase 3Active, not recruiting
- Sponsor
- PharmaMar
- Start
- Mar 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of lurbinectedin, doxorubicin, topotecan, cyclophosphamide and vincristine in small cell lung cancer (SCLC) and bronchial carcinoma (2 arms), sponsored by PharmaMar. Started Mar 2017; status: active, not recruiting.
02
Drugs
lurbinectedindoxorubicintopotecancyclophosphamidevincristine
03
Conditions
small cell lung cancer (SCLC)bronchial carcinoma
Beyond the preview
Go deeper on DRKS00011857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011857.